NEW YORK (GenomeWeb) – Foundation Medicine today said that it has signed a licensing deal with WuXi PharmaTech, enabling that firm to offer Foundation Medicine's genomic profiling technology to companies conducting clinical trials in China.

Under the terms of the agreement, WuXi will perform the laboratory component of Foundation Medicine's FoundationOne test at the WuXi Genome Center in Shanghai, which the firm's noted is the first and only CLIA-certified lab in China. Financial and other tersm of the deal weren't disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.